CHADDS FORD, PA–(EMWNews – July 22, 2008) – Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP) will announce its second quarter financial results on July 31, and

will hold a conference call at

11:00 a.m. ET that day to discuss these results.

David P. Holveck, President and Chief Executive Officer, Nancy J. Wysenski,

Chief Operating Officer, Charles A. Rowland, Jr., Chief Financial Officer,

Ivan Gergel, Executive Vice President, Research and Development and Blaine

Davis, Vice President, Investor Relations & Communications, will host the

call.

Investors and other interested parties may call 888-713-4213 (domestic) or

617-213-4865 (international) and enter code 45330334. Please dial in 10

minutes prior to the scheduled start time.

A replay of the call will be available from July 31 at 1:00 p.m. ET until

12:00 a.m. ET on August 7 by dialing 888-286-8010 (domestic) or

617-801-6888 (international), passcode 15128485.

A simultaneous webcast of the call may be accessed by visiting

www.endo.com. In addition, a replay of the webcast will be available until

12:00 a.m. ET on August 7. The replay can be accessed by clicking on

“Events” in the Investor Relations section of the website.

About Endo

Endo Pharmaceuticals Holdings Inc. is a specialty pharmaceutical company

engaged in the research, development, sale and marketing of branded and

generic prescription pharmaceuticals used primarily to treat and manage

pain. More information, including this and past press releases of Endo

Pharmaceuticals Holdings Inc., is available at www.endo.com.